Sign in
Active, not recruitingNo phase

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

Key facts

Who runs it
Yale University
Where
Atlanta and Indianapolis, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
3,000 people, planned
Started
10 Dec 2015
Expected to end
31 Dec 2030
Type of study
Observational, 6 groups
Record updated
13 February 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (3)Hide the full registry criteria

Who can take part

  • Open to external enrollment:; Subjects with a genetic diagnosis of Marfan Syndrome (MDS), Loeys-Dietz Syndrome (LDS), or Vascular Ehlers-Danlos Syndrome (EDS); (Positive genetic testing or a previous cardiac study required to be eligible); Family members of eligible subjects (Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time)
  • Closed to external enrollment:; Subjects with aortic disease including TAA* or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography); Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease); Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)

Who cannot take part

  • Inability or unwillingness to provide consent (assent when indicated)

Where in United States

  • Childrens Healthcare of AtlantaAtlanta, United States
  • IU School of MedicineIndianapolis, United States

About the trial

What the trial wants to find out

The main purpose of this study is to define the complex genetic and pathogenic basis of thoracic aortic aneurysm (TAA) and other forms of aortopathy and/or aortic valve disease by identifying novel disease-causing genes and by identifying important genetic modifiers for aortic and aortic valve disease severity.

The 6 groups in the trial

  • Aortopathy- Closed to external enrollment

    Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)

  • Syndromic- Open to external enrollment

    Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS) •positive genetic testing and/or a previous cardiac study required to be eligible

  • Aortopathy with Positive Genetic Results- Open to Enrollment

    Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.

  • Aortic Valve Disease- Closed to enrollment

    Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)

  • Family Members- Open to external enrollment

    Family members of eligible subjects •Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time

  • Controls- Closed to external enrollment

    Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 February 2026